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Local application of gentamicin-containing collagen implant in the prophylaxis
and treatment of surgical site infection1. Introduction
The development of surgical site infection (SSI) can be a serious
issue for patients, surgeons and healthcare providers due to the
negative impact on post-operative morbidity and recovery time.
SSIs are estimated to prolong the length of hospital stay and signif-
icantly increase the cost of care. Mandatory surveillance pro-
grammes and improvements in surgical and aseptic technique
have led to a considerable reduction in the incidence of SSI in
many countries and areas of surgery. However, this progress should
not lead to complacency as signiﬁcant challenges remain in the
ﬁght against SSI such as the increasing number of high-risk patients
undergoing surgery and the growing problem of antibiotic
resistance.
In an ageing society, a growing number of patients with one or
multiple co-morbidities will require surgery. The presence of
conditions such as diabetes and obesity in patients has been
demonstrated to increase the risk of SSI in many areas of surgery
and therefore the rising prevalence of these conditions is of great
concern to surgeons and healthcare providers. The World Health
Organisation estimates that by 2030 the number of patients world-
wide with diabetes will reach 366million compared to the ﬁgure of
171 million in 2010.1
The mainstay of SSI prevention in addition to strict aseptic
surgical technique has been the use of systemic antibiotic prophy-
laxis. However, long-term administration of intravenous antibiotics
may lead to a risk of antibiotic resistance and toxicity. The emer-
gence of local antibiotic-eluting products such as resorbable
gentamicin-containing collagen implants (GCCIs) which deliver
high local concentrations of gentamicin with corresponding low
serum levels may help to solve this issue. Local use of gentamicin
delivers a bactericidal concentration that is much higher than that
allowed by systemic injection, so antibiotic blood concentrations
remain low and reduce the chance of adverse effects while the local
drug concentrations are kept high (above the minimal inhibitory
concentration) for at least 48 h. In this way, resistance to antibiotics
caused by low drug dosage is avoided and gentamicin behaves like
a broad-spectrum antibiotic. Furthermore gentamicin-resistant
bacteria are killed by the high local concentration of gentamicin.
This supplement contains detailed overviews of the prophy-
lactic and therapeutic use of GCCI in gastrointestinal, cardiac,
vascular and orthopaedic surgery. The authors have carefully1743-9191/$ – see front matter  2012 Surgical Associates Ltd. Published by Elsevier Lt
doi:10.1016/j.ijsu.2012.05.019reviewed the data and rated the evidence to provide surgeons
with a balanced view of the efﬁcacy and cost-beneﬁt of GCCI with
speciﬁc focus in high-risk procedures and patients.
Two recent randomised studies, failed to show a beneﬁcial
effect of GCCI in the prevention of SSI.2,3 In the two studies the
sponges were immersed in saline before use. This supplement
contains new pharmacokinetic data concerning the elution of
gentamicin from the collagen sponge.4 These data clearly show
that gentamicin is highly water-soluble and is easily rinsed from
the collagen matrix by saline within seconds following immer-
sion. This is an important piece of work by Lovering and
colleagues as it provides a rationale for dry use of GCCI in line
with the manufacturer’s recommendations.
Minimising the development of SSI in high-risk patients is key
to optimising patient outcome and controlling the increasing costs
of healthcare. The development of antibiotic resistance, is still an
issue of major concern despite the introduction of new antibiotics.
Therefore the local route may be an important weapon in the war
against SSI and antibiotic resistance.
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